Focal defect or diffuse wear: why the distinction matters

When a specialist mentions both ChondroFiller and PRP as possible options, the practical question most patients arrive with is: how do I know which one actually applies to my situation? The answer lies not in how much pain you have, but in what your MRI shows.

ChondroFiller is an injectable acellular type I collagen scaffold designed to physically fill a focal, contained cartilage defect — the kind classified as ICRS or Outerbridge grade III–IV, where a discrete structural void exists within an otherwise reasonably healthy joint. PRP is a blood-derived biologic that concentrates platelets and growth factors to reduce intra-articular inflammation, stimulate the body's own repair processes, and slow broader articular wear. It does not fill a structural gap.

This distinction is driven by MRI findings rather than symptom intensity alone. Two patients with identical pain levels may have very different structural pictures, and that structural picture is what guides the clinical decision — a fillable focal defect points toward ChondroFiller territory; diffuse inflammatory wear or early osteoarthritis points toward PRP.

No head-to-head randomised controlled trial comparing the two treatments directly has been published. They rarely represent a straight either/or choice, because they are designed to address different problems. The sections that follow cover each treatment's mechanism and evidence in turn before returning to the question of which patient profile suits which approach.

What ChondroFiller injection is and how it works

Made by Meidrix Biomedicals GmbH and CE-marked as a Class III medical device, ChondroFiller is administered as an ultrasound-guided outpatient injection — no theatre admission, no incisions. Once placed into the defect site, the liquid collagen material gels in situ, conforming to the shape of the structural void.

The process underpinning it is called acellular matrix-induced chondrogenesis. The scaffold itself contains no living cells; instead, it acts as a three-dimensional framework that the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — migrate into and populate over time. A 2025 ex-vivo osteochondral model found ChondroFiller produced a 2.4-fold increase in DNA content by day 14, confirming that cell recruitment does take place within the scaffold. As host tissue matures inside the matrix, the collagen structure gradually resorbs over approximately 6–24 months.

This is not cartilage regrowth in a direct sense. The treatment supports the body's own endogenous repair processes rather than delivering new cartilage from the outside; patient expectations should be framed accordingly.

ChondroFiller is CE-marked for clinical use across Europe but has not received FDA approval, and no active US trial is currently registered. Patient selection is equally critical: the scaffold is intended for focal defects within a joint that does not carry widespread articular degeneration. Hip data from a 26-patient cohort found that individuals with pre-existing Tönnis grade 2–3 osteoarthritis had poor outcomes, establishing advanced generalised OA as a recognised contraindication.

ChondroFiller clinical outcomes: what the studies show

Across four published knee cohort studies and one prospective randomised trial (n=23), ChondroFiller consistently delivered clinically meaningful functional gains. IKDC scores rose from a baseline of approximately 48 to approximately 80 at three years — a ~30-point improvement that exceeds the minimum clinically important difference of 16.7 points. MRI MOCART scores of 81.6–84.3 across European studies confirm structural defect filling of more than 80% in the majority of treated knees, with repair tissue continuing to mature progressively over the twelve-month post-injection period.

Hip data from a 26-patient cohort (12–60 month follow-up) found good or excellent outcomes in 17 of 21 patients who completed the full assessment period. As covered earlier, patients with advanced pre-existing joint degeneration fared poorly — underscoring that thorough MRI-based patient selection before the procedure is not optional.

More recent evidence extends the indication profile. A 2025 wrist feasibility study (n=25) found significantly better cartilage quality at follow-up arthroscopy in ChondroFiller-treated patients versus controls (median Outerbridge 1.5 vs 3.0, p=0.006). The study also flagged a technique-sensitivity point: overfilling defects produced fibrous tissue formation, whereas flush application did not.

One biomechanical finding from a 2024 in-vitro study deserves clear framing: during the early maturation phase the scaffold cannot protect the opposing cartilage surface under joint load. This is precisely why post-injection weight-bearing guidance from the treating clinician is clinically essential, not merely precautionary.

The honest caveats to state alongside those numbers: most studies are small-cohort, and several carry industry sponsorship. The only published RCT (n=23) was compromised by a 60% dropout rate in the comparator arm, preventing a valid head-to-head conclusion. Independent, large-scale trial data remains absent, and critics including US specialist Dr Sabrina Strickland describe the overall evidence base as 'very limited' in high-quality terms.

PRP injections: mechanism, evidence, and the standardisation gap

Preparation method matters considerably when reading PRP research — leukocyte-poor (LP-PRP) and leukocyte-rich (LR-PRP) formulations produce meaningfully different cytokine profiles, which partly explains the variability in outcomes across the clinical literature.

PRP is derived from the patient's own blood, centrifuged to concentrate platelets, growth factors, and cytokines. Once injected intra-articularly, it modulates the inflammatory environment, stimulates chondrogenic signalling pathways, may support type-II collagen production, and has been associated on MRI with slowing articular cartilage degeneration. The typical pain-relief window in clinical practice is roughly 6–12 months, after which re-injection may be considered.

A 2022 narrative review of 13 clinical trials (PMC, cited 64 times) confirmed that most studies report a positive effect on cartilage injury and joint function across multiple biological pathways. The important caveat the same review identifies: no standardised preparation protocol, platelet concentration target, dosing schedule, or activation method exists across the published literature. Without knowing the preparation specifics, comparing one PRP study against another is unreliable — a limitation that affects how confidently any single trial's results can be generalised.

Brittberg's 2024 state-of-the-art knee cartilage review positions PRP as a biological adjunct to repair procedures — augmenting bone marrow stimulation or scaffold placement, for example — rather than as a standalone structural solution for full-thickness focal defects. Where PRP performs most credibly as a primary treatment is in diffuse inflammatory wear and early osteoarthritis: contexts where modulating the joint's biological environment is the therapeutic goal.

Choosing between ChondroFiller and PRP: a practical framework

The clinical logic the evidence supports runs roughly as follows: an MRI-confirmed focal, contained cartilage void graded ICRS or Outerbridge III–IV in an otherwise healthy joint points towards assessment for a ChondroFiller injection pathway, where the scaffold's role is structural filling and host-cell recruitment. Diffuse articular wear, early osteoarthritis, or post-procedural biological support point towards PRP, where the goal is modulating the joint's inflammatory and regenerative environment rather than addressing a discrete structural void.

The two treatments are not mutually exclusive by nature. Ex-vivo data showing a 2.4-fold increase in host-cell recruitment within the ChondroFiller scaffold — with further gains when mesenchymal stem cells were added — raise the possibility that a biologic adjunct could augment scaffold-based repair. No formal combination-protocol studies have been published yet, so this remains an emerging hypothesis rather than an established clinical pathway.

Several evidence gaps bear on that framework. No head-to-head RCT comparing ChondroFiller with PRP has been conducted, so the decision logic above is drawn from separate evidence streams rather than direct comparative data. Published follow-up for ChondroFiller in the knee reaches approximately five years; data beyond that point have not yet been reported. PRP's effectiveness in any individual patient is also difficult to predict without knowing the preparation specifics — a limitation the field has not yet resolved through standardised protocols.

Taken together, these gaps mean that treatment selection depends on an imaging-informed specialist assessment rather than symptom pattern alone. The MRI profile, defect size, joint condition, and individual clinical history are the determinants — and each carries weight that no self-selection framework can substitute for.

Finding a specialist for ChondroFiller or PRP injection

Both ChondroFiller and PRP injections are delivered as ultrasound-guided outpatient procedures — but reaching the right one begins with a structured specialist assessment, not the injection itself. Bringing existing MRI images or reports to that appointment gives the clinician the defect-level detail needed to determine whether a focal, fillable structural void is present, or whether diffuse articular changes make a biological pathway more appropriate. Three questions are worth raising directly: What does my MRI show about defect size and containment? Am I a candidate for ChondroFiller, PRP, or a combination approach? And what weight-bearing or activity restrictions would apply in the weeks following injection, given the biomechanical maturation phase the scaffold requires?

Search MSK lists specialists across the UK who offer ChondroFiller injection and PRP — filter by region and specialty to find one suited to your situation.